24th May 2006 10:45
Hikma Pharmaceuticals Plc24 May 2006 Section 198 Notification London, 24 May 2006 - On 23rd May 2006, Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) ("the Company") received notification from The Capital Group Companies, Inc., pursuant to Section 198 Companies Act 1985, that at the close of its business on 19th May 2006, The Capital Group Companies, Inc., on behalf of its affiliates, including Capital Research and Management Company, had an interest in 5,251,350 ordinary shares of 10p each in the Company, which represents 3.14 per cent of the issued ordinary share capital of the Company, as follows: No. of shares Capital Research and Management Company 5,251,350held as follows: State Street Nominees Limited 4,097,500 Chase Nominees Limited 1,153,850 - ENDS - Enquiries: Hikma Pharmaceuticals PLC +44 20 7399 2670Henry Knowles, Company SecretarySusan Ringdal, Investor Relations Director Brunswick Group LLP +44 20 7404 5959Jon Coles / Wendel Verbeek / Justine McIlroy / AlexTweed Notes to Editors About HikmaHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals